Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Antiviral Res. 2019 Apr 7;167:25–34. doi: 10.1016/j.antiviral.2019.04.004

Figure 5. Prophylactic efficacy of ML336 and BDGR-4 tested in BALB/c mice challenged with VEEV TrD.

Figure 5.

Groups of four BALB/c mice per treatment, vehicle, ML336 or BDGR-4, were assessed for survival over 21 days following a s.c. challenge with 10LD50 VEEV TrD. ML336 or BDGR-4 were dosed at 12.5 mg/kg BID delivered by i.p.. Treatments were administered i.p. in a volume of 0.1 ml in 25% PEG400/10% RH40/65% water starting at 2 hours prior to virus infection (D0) and were given BID through D7.